The Clinical Pharmacokinetics of Cladribine
- 1 February 1997
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 32 (2) , 120-131
- https://doi.org/10.2165/00003088-199732020-00003
Abstract
Cladribine is a new purine nucleoside analogue with promising activity in low-grade lymphoproliferative disorders, childhood acute myelogenous leukaemia and multiple sclerosis. Reversed phase high...Keywords
This publication has 53 references indexed in Scilit:
- Oral 2‐chlorodeoxyadenosine in psoriaticArthritis & Rheumatism, 1995
- Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugsAnti-Cancer Drugs, 1995
- Analysis of 2-Chloro-2'-Deoxyadenosine in Human Blood Plasma and Urine by High-Performance Liquid Chromatography Using Solid-Phase ExtractionTherapeutic Drug Monitoring, 1994
- Cladribine in treatment of chronic progressive multiple sclerosisThe Lancet, 1994
- The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.1994
- CladribineDrugs, 1993
- 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.Journal of Clinical Oncology, 1993
- Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ?first-pass? metabolismEuropean Journal of Clinical Pharmacology, 1992
- A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.Journal of Clinical Oncology, 1991
- Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.Proceedings of the National Academy of Sciences, 1980